| Market Capitalization (Millions $) |
1,335 |
| Shares
Outstanding (Millions) |
108 |
| Employees |
104 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-140 |
| Cash Flow (TTM) (Millions $) |
-19 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Oric Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that specializes in developing targeted cancer treatments. The company was founded in 2014 and has its headquarters in Durham, North Carolina. Its mission is to develop innovative cancer therapies that are designed to overcome tumor resistance and improve patient outcomes.
The company's approach to cancer treatment is based on the concept of oncogene addiction. Oncogene addiction is a phenomenon where cancer cells become dependent on a particular oncogenic driver pathway for survival and proliferation. Oric's drug development programs are focused on inhibiting these oncogenic pathways to induce cancer cell death or halt tumor growth.
Oric has two lead drug candidates in clinical development, ORIC-101 and ORIC-53 ORIC-101 is a potent and selective inhibitor of the serine/threonine kinase AKT, which is involved in multiple oncogenic signaling pathways. The drug is being evaluated in phase 1b and 2 clinical trials for the treatment of solid tumors harboring AKT mutations, amplifications, or other dysregulations. ORIC-533, on the other hand, is a small molecule inhibitor of the CD73 enzyme, which plays a role in tumor immune evasion. The drug is being developed for the treatment of various solid tumors, including bladder, breast, and ovarian cancer.
In addition to its clinical pipeline, Oric has a preclinical portfolio of development-stage programs targeting various oncogenic drivers, such as KRAS and EGFR. The company leverages various scientific approaches, including machine learning algorithms and functional genomics, to identify and validate new cancer targets.
Oric has established partnerships with several leading academic institutions, such as Memorial Sloan Kettering Cancer Center and the University of California, San Francisco, to advance its drug development programs. The company also collaborates with other biopharmaceutical companies, such as Taiho Pharmaceutical and AstraZeneca, to explore new drug combinations and treatment approaches.
Overall, Oric Pharmaceuticals Inc. is a promising biotech company that is focused on developing precision cancer therapies that could potentially transform cancer treatment and improve patient outcomes.
Company Address: 240 E. Grand Ave South San Francisco 94080 CA
Company Phone Number: 388-5600 Stock Exchange / Ticker: NASDAQ ORIC
|
